Clinical perspectives of PARP inhibitors
- 31 July 2005
- journal article
- review article
- Published by Elsevier BV in Pharmacological Research
- Vol. 52 (1), 109-118
- https://doi.org/10.1016/j.phrs.2005.02.013
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical ApplicationsProgress in Biophysics and Molecular Biology, 2005
- Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agentOncogene, 2004
- WY 14643, A POTENT EXOGENOUS PPAR-?? LIGAND, REDUCES INTESTINAL INJURY ASSOCIATED WITH SPLANCHNIC ARTERY OCCLUSION SHOCKShock, 2004
- Poly(ADP-ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditionsInternational Journal of Cancer, 2004
- Crosstalk between PARP-1 and NF-κB modulates the promotion of skin neoplasiaOncogene, 2004
- Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cellsCell Death & Differentiation, 2001
- Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: Evidence for increased tumor cell apoptosis in vivoOncogene, 1999
- Apoptosis in the Absence of Poly- (ADP-ribose) PolymeraseBiochemical and Biophysical Research Communications, 1997
- Inactivation of the Poly(ADP-ribose) Polymerase Gene Affects Oxygen Radical and Nitric Oxide Toxicity in Islet CellsPublished by Elsevier BV ,1995